Veracyte, Inc.: Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022

New data support continued expansion of the company's tests, including determining treatment prognosis in men with advanced prostate cancer Veracyte, Inc. (Nasdaq: VCYT) announced today that seven

Related Keywords

California ,United States ,Paris ,France General ,France ,South San Francisco ,Singapore ,American ,Marc Stapley ,Edwardm Schaeffer ,Giuseppe Curigliano ,Marina Perry ,Ashley Ross ,Shayla Gorman ,Phuoc Tran ,Tracy Morris ,Paul Nguyen ,Feinberg School Of Medicine At Northwestern University ,Twitter ,Nasdaq ,National Cancer Centre Singapore ,Research Use ,Ar Activity Prognosticates Development Of Castration ,Global Corporate Communications ,University Of Maryland School Medicine ,Veracyte Inc ,European Society For Medical Oncology ,University College London Cancer Institute ,European Society ,Medical Oncology ,Decipher Prostate ,Counter Analysis System ,Transcriptomic Signature ,Prognosticates Development ,Metastasis Directed Therapy ,Maryland School ,Northwestern Medicine ,Basal Luminal Subtyping Classifier ,High Risk Prostate Cancer ,Feinberg School ,Northwestern University ,East Asian ,North American ,Decipher Prostate Genomic ,Annual Report ,Quarterly Report ,Nanostring Technologies ,Decipher Prostate Genomic Classifier ,Research Use Only ,Investor Relations ,Veracyte ,Nnounces ,Seven ,Abstracts ,Resented ,Osmo ,Congress ,022 ,